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The work by Cheung and colleagues, in this issue of Cancer Cell, demonstrates another example of how
lineage-specific transcriptional regulators of differentiation, GATA6 and HOPX, can control the fate of lung
adenocarcinoma progression.Lineage-specific transcriptional regula-
tors govern differentiation status during
normal lung development as well as in
lung adenocarcinoma. Aberrant activa-
tion or inactivation of transcriptional reg-
ulators important for lineage commit-
ment have been frequently observed in
hematopoietic malignancies such as
PAX5 deletion and TAL1 translocation in
acute lymphocytic leukemia and RUNX1
and RARA translocations in acute mye-
logenous leukemia. There has been
emerging evidence that tissue-specific
differentiation programs also become
dysregulated during cancer evolution in
solid tumors. ETS family members are
frequently translocated in prostate can-
cer, and a lineage-restricted genomic
amplification of developmental trans-
cription factors occurs frequently in solid
tumors, as exemplified by MITF in mela-
noma, NKX2-1 in lung adenocarcinoma,
and SOX2 in lung and esophageal squa-
mous cell carcinomas.
In the orderly development of tissues,
temporally and spatially controlled mito-
genic signaling directs cell lineages to
proliferate and/or migrate. However, over
the course of cancer evolution, cells
accumulate genomic and/or epigenomic
alterations to adapt their lineage identity
to support persistent oncogenic signal
activation. These adapted differentiation
states often predict the fate of cancer
progression. For example, poorly differen-
tiated lung adenocarcinomas, the most
divergent differentiation state from the
normal respiratory unit, generally have
the worst prognosis, whereas, for sub-
types of lung adenocarcinoma that moreclosely resemble normal progenitors, the
prognosis varies among subtypes classi-
fied based on architectural patterns that
resemble normal differentiation status
(Yoshizawa et al., 2011) (Figure 1).
Studies using animal models of lung
adenocarcinoma have shown that tu-
mors with dysregulated developmental
transcriptional regulators indeed present
with differential biological properties. In
the case of NKX2-1, the most well-char-
acterized example of a transcriptional
regulator of lung adenocarcinoma dif-
ferentiation, stochastic loss of mouse
Nkx2-1 promotes de-differentiation and
metastasis in a model of Kras-driven
lung adenocarcinoma (Winslow et al.,
2011), while discrete Nkx2-1 deletion in-
duces endodermal trans-differentiation
and increases tumor initiation and pro-
gression (Maeda et al., 2012; Snyder
et al., 2013). However, the consequences
of an altered differentiation program are
context-dependent, as shown by Maeda
et al. (2012), where haplo-insufficiency of
Nkx2-1 conversely decreased the inci-
dence and progression of Egfr-driven
lung adenocarcinomas. These results
are consistent with the heterogeneity of
human lung adenocarcinomas where tu-
mors with low NKX2-1 expression have
generally worse prognoses while onco-
genic amplification of NKX2-1 is also
found in a subset of the disease.
Another developmental pathway, WNT/
TCF signaling, has also been shown to
mediate lung adenocarcinoma progres-
sion and metastasis. The TCF4 transcrip-
tional signature is associated with human
lung adenocarcinoma recurrence, andCancer Cellmaintenance of TCF4 activity through its
downstream effectors, including LEF1
and HOXB9, in metastatic derivatives of
lung adenocarcinoma cell lines is required
for metastatic potential in a xenograft
model (Nguyen et al., 2009). In highly met-
astatic Lkb1-deficient Kras-driven lung
tumors, progression to metastasis is
associated with signatures of b-catenin
activity, epithelial-mesenchymal transi-
tion (EMT), and focal adhesion (Carretero
et al., 2010). In addition, in a transgenic
mouse model, constitutively active b-cat-
enin cooperates with oncogenic Kras to
enhance tumor development and de-dif-
ferentiation to an immature distal epithe-
lial lineage through increased expression
of Id2 and Sox9 and a decreased expres-
sion of Hopx (Pacheco-Pinedo et al.,
2011). Thus, there seems to be interplay
between WNT/TCF signaling and tran-
scriptional regulators of differentiation in
the lung.
The study by Cheung et al. (2013) in this
issue of Cancer Cell describes an ‘‘alve-
olar’’ gene signature compiled from the
published transcriptomic data of several
experimental alveolar differentiation phe-
notypes, which further anti-correlates
with an embryonic stem cell signature
and can cluster lung adenocarcinomas
into two subgroups: ‘‘alveolar-like’’ and
‘‘distal airway stem cell-like’’. The ‘‘alve-
olar-like’’ subgroup represents histologi-
cally more differentiated lung adenocar-
cinomas with decreased incidence of
metastasis. The alveolar-like subgroup
was characterized by increased expres-
sion levels of NKX2-1, GATA6, and their
known interactor HOPX, consistent with23, June 10, 2013 ª2013 Elsevier Inc. 707
Figure 1. Metastatic Potential Varies among Subtypes of Lung Cancer Defined by
Transcriptional Regulation of Cell Lineages
Transcriptional regulators active in different cell lineages are shaded in green (WNT/TCF), yellow (SOX2),
orange (FOXA1), red (NKX2-1), and blue (GATA6/HOPX). Arrows indicate differentiation. Curved arrows
indicate malignant transformation.
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murine Kras-driven lung adenocarci-
nomas (Winslow et al., 2011).
Cheung et al. (2013) further demon-
strate that GATA6 and HOPX coopera-
tively suppress in vitro invasion and
metastatic potential in xenograft models
using human lung adenocarcinoma cell
lines. GATA6, another key transcrip-
tional regulator in lung morphogenesis,
is essential for the maturation of alveolar
type I epithelial cells. Furthermore, HOPX
has been shown to regulate alveolar cell
maturation in vivo by suppressing surfac-
tant protein production downstream of
NKX2-1 and GATA6 activity in the devel-
oping airway (Yin et al., 2006). Therefore,
it is plausible that the cooperative func-
tion of GATA6 and HOPX is to direct a
subpopulation of alveolar type II cells
toward a more mature state, which will
then terminally differentiate into alveolar
type I cells. Furthermore, it suggests that
the repression of this pro-differentiation
function confers a more invasive and
metastatic lung adenocarcinoma pheno-
type (Figure 1).
Interestingly, Cheung et al. (2013)
found these effects were not mediated
through b-catenin activity or EMT, but708 Cancer Cell 23, June 10, 2013 ª2013 Elsrather by suppression of squamoid
differentiation, the gene signature of
which includes expression of KRT6A
and KRT6B. While GATA6 has been
shown to suppress expansion of bron-
chiolar epithelial cells through inhibition
of the b-catenin pathway in developing
and regenerating lungs, Gata6 is not
required for the earliest stages of lung
branching, but is expressed throughout
the developing foregut endoderm (Zhang
et al., 2008). In the esophagus, where
stratified squamous epithelium is native,
GATA6 serves as an amplified lineage
oncogene in metaplastic adenocarci-
nomas (Lin et al., 2012). Therefore, the
role of GATA6 may generally be to
suppress differentiation to the stratified
squamous epithelial lineage.
Another interesting finding of the
Cheung et al. (2013) study is that, unlike
Nkx2-1 in mouse models of lung cancer,
the genotypes of the major driver onco-
genes, KRAS and EGFR, in the two lung
adenocarcinoma cell lines primarily used
in this study did not have differential
effects on metastatic phenotype. Consis-
tent with this result, the ‘‘alveolar’’ sub-
group is not associated with particular
genotypes of KRAS, EGFR, STK11, andevier Inc.TP53. However, the high level of genomic
complexity in human cancer cell lines
makes it difficult to interpret the influence
of a single genotype, and it would be of
interest to test whether these observa-
tions are genotype-specific within genet-
ically defined autochthonous in vivo
models.
The work by Cheung et al. (2013)
provides mechanistic insight into how
lineage factors play roles in maintaining
cellular identity within tumors: in some
cases deleterious for cancer fitness,
invasion, and/or metastasis while advan-
tageous in other cases. Cancer cells
are typically characterized by reduced
developmental plasticity or fixation at a
particular developmental point within a
lineage, which are ordinarily tightly regu-
lated in tissue development in part
through the accumulation of genomic
alterations. Whereas studies of genomic
alterations that lead to activation or inac-
tivation of signaling molecules in lung
adenocarcinoma have been fruitful, the
molecular regulators of lung adenocar-
cinoma differentiation, and indeed of
differentiation in normal lung alveolar
epithelium, remain poorly understood.
Therefore, further investigation of dysre-
gulated transcriptional networks in solid
tumors may provide clues to the stages
of normal lung epithelial development
as well as identify additional important
tumor vulnerabilities.
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Epigenetic reprogramming is a feature of many human cancers. In this issue of Cancer Cell, Letouze´ and
colleagues describe DNA hypermethylation in paragangliomas harboring mutations in succinate dehydroge-
nase genes. These tumors accumulate succinate, which inhibits 2-oxoglutarate-dependent histone and DNA
demethylase enzymes, resulting in epigenetic silencing that affects neuroendocrine differentiation.Metabolic rewiring has long been re-
garded as a consequence of malignant
transformation driven by abnormal signal
transduction mediated by oncogenes
and tumor suppressors. The identification
that the metabolite (R)-2-hydroxygluta-
rate [(R)-2HG] plays an oncogenic role in
subsets of gliomas and acute myeloge-
nous leukemia with mutations in isoforms
of isocitrate dehydrogenase (IDH) has
provided direct evidence linking altered
metabolism and cancer and founded the
notion of the ‘‘oncometabolite’’ (Ward
et al., 2010). (R)-2HG is a product of the
neomorphic activities of mutant IDH1/2
and accumulates to millimolar concentra-
tions in IDH-associated gliomas (Dang
et al., 2010). Due to the structural similar-
ity to 2-oxoglutarate (2OG), (R)-2HG
competitively inhibits the 2OG-utilizing
Jumonji C (JmjC)-domain containing his-
tone lysine demethylases and the TET
family of 5-methylcytosine (5mC) hydrox-
ylases, leading to DNA hypermethylation
at CpG islands in promoter regions of
genes involved in cell differentiation (Kim
and DeBerardinis, 2013).
The Krebs cycle enzymes succinate
dehydrogenase (SDH) and fumarate
hydratase (FH) are tumor suppressors
whose loss-of-function mutations predis-
pose to familial cancer syndromes (Frezzaet al., 2011). SDH and FH inactivation
results in a blockade of Krebs cycle,
impaired respiration, and abnormal accu-
mulation of their substrates succinate and
fumarate, respectively. Both metabolites
are also inhibitors of 2OG-dependent
dioxygenases, particularly the hydroxy-
lases for the transcription factor hypoxia-
inducible factor (HIF), resulting in
HIF-dependent activation of a ‘‘pseudo-
hypoxic’’ response characterized by
enhanced angiogenesis and increased
anaerobic metabolism (Frezza et al.,
2011). In the case of fumarate, the metab-
olite is also an endogenous electrophile
and can chemically modify cysteine
residues in Kelch-like ECH-associated
protein 1, leading to constitutive (and
potentially oncogenic) activation of tran-
scription factor nuclear factor erythroid
2-related factor 2 (Adam et al., 2011; Ooi
et al., 2011). Until recently, HIF activation
by fumarate and succinate has been the
only mechanistic link to oncogenesis that
hasbeendescribed inFH andSDHmutant
cancer models (Pollard et al., 2007; Selak
et al., 2005). However, at least in the
context of FH-deficiency, a causal role
for HIF in tumorigenesis is questionable
(Adamet al., 2011), and the quest for other
oncogenic drivers inSDH- andFH-associ-
ated malignancy continues. Recent re-ports by Killian et al. (2013) and Letouze´
et al. (2013; in this issue of Cancer Cell)
both demonstrate that, similarly to (R)-
2HG, succinate can also remodel the epi-
genome and alter gene expression.
SDHmutations occur frequently in par-
aganglioma (PGL), pheochromocytoma
(PCC), gastrointestinal stromal tumor
(GIST), as well as in renal carcinoma (Kill-
ian et al., 2013). GIST tumors can alterna-
tively be driven by mutations in signal
transduction kinases. Killian et al. (2013)
compared the methylation profiles of
GISTs with mutations in either SDH or
KIT tyrosine kinase and uncovered
marked global hypermethylation in the
SDH versus KIT mutant subgroup.
Further examination of a PGL/PCC cohort
showed a similar hypermethylation phe-
notype in SDH mutant tumors compared
to SDH-wild-type reference tissues.
Bioinformatic analyses of methylomes
from developmentally distinct tumors
including GIST, PGL, PCC, and gliomas
revealed comparable methylation signa-
tures in those harboring SDH and IDH
mutations (Killian et al., 2013).
Letouze´ et al. (2013) classified a
large PGL/PCC cohort based on DNA
methylation and obtained three stable
clusters. Strikingly, a distinct subgroup
characterized by the presence of a23, June 10, 2013 ª2013 Elsevier Inc. 709
